Table of Content

1 INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study


2 RESEARCH METHODOLOGY


3 EXECUTIVE SUMMARY


4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Growing Number of Cross-industry Collaborations and Partnerships
4.2.2 Surge In Adoption of Artificial Intelligence (AI) for Clinical Trials
4.2.3 Increasing Need to Reduce Drug Discovery & Development Costs and Timelines
4.3 Market Restraints
4.3.1 Inadequate Availability of Skilled Professionals
4.3.2 Incompatible Healthcare IT Infrastructure
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry


5 MARKET SEGMENTATION (Market Size by Value - USD million)
5.1 By Technology
5.1.1 Machine Learning
5.1.2 Other Technologies
5.2 By Type
5.2.1 Software
5.2.2 Services
5.3 By Application
5.3.1 Drug Discovery
5.3.2 Clinical Trial
5.3.3 Laboratory Automation
5.3.4 Others
5.4 Geography
5.4.1 North America
5.4.1.1 United States
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 United Kingdom
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia-Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Middle East
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle East
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America


6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Alphabet Inc. (Isomorphic Laboratories)
6.1.2 BenevolentAI
6.1.3 XtalPi Inc.
6.1.4 Cloud Pharmaceuticals, Inc.
6.1.5 Deep Genomics
6.1.6 Euretos
6.1.7 Exscientia
6.1.8 IBM Corporation
6.1.9 Insilico Medicine
6.1.10 NVIDIA Corporation


7 MARKET OPPORTUNITIES AND FUTURE TRENDS